



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address : COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
06/313,601	10/21/81	KAPLAN J	HCN18524

REGNER & BRETSCHNEIDER
STE. 740, 1920 N STREET, N.W.
WASHINGTON, DC 20036

EXAMINER	
DENTZ, B	
ART UNIT	PAPER NUMBER
121	3

DATE **MAILED**

This is a communication from the examiner in charge of your application.

COMMISSIONER OF PATENTS AND TRADEMARKS

MAY 19 1982

GROUP 120

☒ This application has been examined. ☐ Responsive to communication filed on _____ ☐ This action is made final.

A shortened statutory period for response to this action is set to expire 3 month(s), _____ days from the date of this letter.
Failure to respond within the period for response will cause the application to become abandoned. 35 U.S.C. 133

Part I THE FOLLOWING ATTACHMENT(S) ARE PART OF THIS ACTION:

- ☒ Notice of References Cited by Examiner, PTO-892
- ☐ Notice of Informal Patent Drawing, PTO-948
- ☐ Notice of References Cited by Applicant, PTO-1449
- ☐ Notice of Informal Patent Application, Form PTO-152

Part II SUMMARY OF ACTION

- ☒ Claims 1-8 are pending in the application.
Of the above, claims _____ are withdrawn from consideration.
- ☐ Claims _____ have been cancelled.
- ☐ Claims _____ are allowed.
- ☒ Claims 1-8 are rejected.
- ☐ Claims _____ are objected to.
- ☐ Claims _____ are subject to restriction or election requirement.
- ☐ The formal drawings filed on _____ are acceptable.
- ☐ The drawing correction request filed on _____ has been ☐ approved. ☐ disapproved.
- ☒ Acknowledgment is made of the claim for priority under 35 U.S.C. 119. The certified copy has
☒ been received. ☐ not been received. ☐ been filed in parent application, serial no. _____
filed on _____
- ☐ Since this application appears to be in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.
- ☐ Other

Claims 1-8 are rejected under 35 USC 103 as being obvious from the British Patent, Almirante et. al. I, Shen and Almirante et. al. II. Although, the invention is not identically disclosed or described as set forth in section 102 of this title, the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. The British Patent discloses 2-(halo and alkyl phenyl) imidazo [1, 2-a] pyridine-3-acetamides useful as pharmaceuticals. They are disclosed as having anti-convulsant, analgesic, antipyretic, and anti-phlogistic activity. The instant compounds differ in having at least one substituent on the amide nitrogen. Claim 2 recites the N,N-dialkyl acetamido group. Almirante et. al. and Shen render this modification obvious by disclosing in related compounds the desirability from a pharmaceutical property standpoint of mono and disubstituted amino and carboxamido groups. See page 310 and compounds 22 and 30 of the former and columns 1 and 2 of Shen. Shen is concerned with indomethacin type compounds-, but Almirante et. al. II discloses that the instant compounds may be considered analogs of indomethacin at page 122.

Serial No. 313,601

-3-

Art Unit 121

Claim 8 is rejected under 35 USC 112, second paragraph as failing to particularly point out the invention. The specific utility must be recited in the composition claim as well as the amount of active ingredient.

D
Dentz:ebw

A/C 703

557-2517

04/20/82

Henry R. Miles
Supervisory Patent Examiner
Art Unit 121

